These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36609023)

  • 1. Novel Flow Cytometry-Based Method for Detection of Anti-HLA Complement Activating Donor-Specific Antibodies in Renal Transplant Recipients and Its Comparison With Other Conventional Detection Methods.
    Rani L; Singh H; Saikia B; Aggarwal R; Kumar Y; Kumar M; Chhabra S; Kumar M; Kumar B; Kumar V; Das P; Sharma A; Ramchandran R; Kohli HS; Minz RW
    Transplant Proc; 2023; 55(1):134-139. PubMed ID: 36609023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Luminex-Based Single Antigen Based Results With Complement-Dependent Cytotoxicity Crossmatch and Flow Cytometry Crossmatch Results: A Single-Center Experience From Istanbul.
    Oguz SR; Sinangil A; Barlas S; Ciftci HS; Ulusoy E; İzgi DK; Ogret Y; Ecder T; Akin B
    Transplant Proc; 2023 Mar; 55(2):303-308. PubMed ID: 36890054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement-dependent cytotoxicity crossmatch in solid organ transplantation: The gold standard or golden history?
    Tafulo S; Osório E; Mendes C; Liwski R
    Hum Immunol; 2024 Jan; 85(1):110734. PubMed ID: 38030522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of donor-specific HLA antibodies: A retrospective observation in 350 renal transplant cases.
    Pandey P; Pande A; Mandal S; Marik A; Devra AK; Sinha VK; Bhatt AP; Gajway SY; Singh RK; Mishra S; Jha S
    Transpl Immunol; 2023 Apr; 77():101783. PubMed ID: 36608831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual crossmatch in kidney transplantation.
    Piazza A; Ozzella G; Poggi E; Caputo D; Manfreda A; Adorno D
    Transplant Proc; 2014 Sep; 46(7):2195-8. PubMed ID: 25242749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of complement-dependent lymphocytotoxicity crossmatch and flow cytometry crossmatch results versus Luminex single-antigen bead-based donor-specific IgG class I antibody MFI values in live related renal transplant cases; a retrospective observation in 102 cases.
    Pandey P; Pande A; Kumar Devra A; Kumar Sinha V; Prasad Bhatt A
    J Immunoassay Immunochem; 2021 May; 42(3):300-313. PubMed ID: 33356865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of Luminex-based single antigen class II bead assay and its mean fluorescence intensity in renal transplant cases; a retrospective observation in 97 cases.
    Pande A; Pandey P; Kumar Devra A; Kumar Sinha V; Prasad Bhatt A
    J Immunoassay Immunochem; 2020 May; 41(3):322-336. PubMed ID: 32122239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric detection of complement-activating HLA antibodies.
    Schönemann C; Lachmann N; Kiesewetter H; Salama A
    Cytometry B Clin Cytom; 2004 Nov; 62(1):39-45. PubMed ID: 15476206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing number of laboratories performing complement dependent cytotoxicity crossmatching: Reasons and conclusions.
    Putheti P; Liwski RS; Jindra PT
    Hum Immunol; 2022 May; 83(5):467-475. PubMed ID: 35183390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
    Tait BD; Süsal C; Gebel HM; Nickerson PW; Zachary AA; Claas FH; Reed EF; Bray RA; Campbell P; Chapman JR; Coates PT; Colvin RB; Cozzi E; Doxiadis II; Fuggle SV; Gill J; Glotz D; Lachmann N; Mohanakumar T; Suciu-Foca N; Sumitran-Holgersson S; Tanabe K; Taylor CJ; Tyan DB; Webster A; Zeevi A; Opelz G
    Transplantation; 2013 Jan; 95(1):19-47. PubMed ID: 23238534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of Luminex-crossmatch assay and its mean fluorescence intensity - a retrospective observation in 380 renal transplant cases.
    Pandey P; Pande A; Mishra S; Setya D; Devra AK; Sinha VK; Bhatt AP
    Pol Przegl Chir; 2022 Apr; 94(2):38-48. PubMed ID: 35485317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Rapid Optimized 96-well Tray Flow Cytometric Crossmatch (Halifax-FCXM) with Luminex Single Antigen Test.
    Yoo J; Lee S; Lee HW; Lee S; Choi J; Han J; Kang H; Choi A; Hee Jang J; Oh EJ
    Hum Immunol; 2021 Apr; 82(4):302-308. PubMed ID: 33744026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.
    Zeevi A; Lunz J; Feingold B; Shullo M; Bermudez C; Teuteberg J; Webber S
    J Heart Lung Transplant; 2013 Jan; 32(1):98-105. PubMed ID: 23142561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic flow cytometric crossmatch in renal transplantation: a single assay to simultaneously detect antibody binding and cytotoxicity.
    Thammanichanond D; Athimang W; Paisooksantivatana K; Mongkolsuk T; Ingsathit A; Worawichawong S; Kitpoka P; Jirasiritham S; Kantachuvesiri S
    Transplant Proc; 2012 Jan; 44(1):62-5. PubMed ID: 22310580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with complement-dependent cytotoxicity & flow crossmatch results in live donor renal transplantation.
    Baranwal AK; Bhat DK; Goswami S; Agarwal SK; Kaur G; Kaur J; Mehra N
    Indian J Med Res; 2017 Feb; 145(2):222-228. PubMed ID: 28639599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Causes of Positive Pretransplant Crossmatches in the Absence of Donor-Specific Anti-Human Leukocyte Antigen Antibodies: A Single-Center Experience.
    Kang H; Yoo J; Lee SY; Oh EJ
    Ann Lab Med; 2021 Jul; 41(4):429-435. PubMed ID: 33536364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Pretransplant Donor-Specific Alloantibodies With Different Crossmatch Techniques.
    Moszkowska G; Zieliński M; Zielińska H; Dukat-Mazurek A; Dębska-Zielkowska J; Dębska-Ślizień A; Rutkowski B; Trzonkowski P
    Transplant Proc; 2018; 50(6):1625-1630. PubMed ID: 30056871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified flow cytometry crossmatch detecting alloantibody-related cytotoxicity as a way to distinguish lytic antibodies from harmless in allosensitised kidney recipients.
    Zieliński M; Zielińska H; Moszkowska G; Dȩbska-Ślizień A; Rutkowski B; Trzonkowski P
    Transplant Proc; 2013; 45(1):88-94. PubMed ID: 23375279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.